Core Viewpoint - The company is focusing on enhancing its market presence and brand value in potential markets, particularly in Inner Mongolia, through specialized training programs for its partners and staff [2][8]. Group 1: Training Program Overview - The training program, named "Pian Zai Huang National Medicine Hall Professional Empowerment Training," was successfully held in Hohhot and Ordos, aimed at improving the professional skills and service capabilities of terminal staff [1][2]. - The training is part of the company's strategic initiative to penetrate potential markets, with Inner Mongolia selected for its strategic importance as a connection point between the Northwest and Northeast regions [2]. Group 2: Training Content and Structure - The training included a comprehensive curriculum focusing on product knowledge, marketing strategies, and customer service skills, ensuring participants understand the value of the products and can provide reliable health consultations [3][4]. - The program also emphasized the integration of local cultural elements, such as the introduction of "Zhangzhou Six Infusions Tea," to enhance customer satisfaction and create a differentiated service experience [5]. Group 3: Training Outcomes - The training adopted a "theory + interaction + practical application" model, resulting in a 100% pass rate for knowledge exams and practical assessments, indicating a significant improvement in participants' service standards and confidence [6][7]. - A satisfaction survey revealed a 100% satisfaction rate among participants, reflecting the effectiveness of the training in enhancing their skills [7]. Group 4: Future Plans - The company plans to replicate the successful training model across other potential markets in Northeast and Northwest China, ensuring the sustainability of the training outcomes and supporting the brand's growth [8].

8月6日晚间，片仔癀(600436)披露关于投资参与高鑫润信基金的公告。近日，全资子公司漳州片仔癀投 资管理有限公司(下称"片仔癀投资")与中信建投资本管理有限公司等头部企业拟共同投资设立漳州高鑫 润信大健康产业投资合伙企业(有限合伙)，募资总额10亿元。 值得一提的是，由漳州圆山大健康产业基金投资的上市公司广生堂(300436.SZ)，因其慢性乙肝治疗新 药出色的Ⅱ期临床数据，在此轮创新药估值修复中被资本市场高度认可。据统计，自2024年11月14日广 生堂完成权益变动，圆山基金正式入股成为其前十大股东之一，持股比例5.02%，至今年8月4日收盘， 广生堂股价已实现了超过300%的上涨，成为中药企业向创新药战略延伸的典型案例。 作为有限合伙人，片仔癀投资将以自有资金认缴出资2亿元，占高鑫润信基金目标募集规模的比例为 20%。 公告指出，高鑫润信基金拟投资领域，包含药品、医疗器械、医疗健康上游供应链及零部件、食品保健 品、合成生物、化工材料、消费医疗等大健康相关领域，医疗健康以外的其他领域投资占比不超过本基 金认缴出资规模的10%。 值得关注的是，此次设立发起的高鑫润信基金是漳州市"圆山计划"的一环。据了解， ...

Group 1 - The company, Pianzaihuang, has announced its investment in the Zhaoying Huikang Fund, contributing 200 million yuan, which represents 20% of the fund [1] - The investment is part of the company's strategic development plan, aimed at enhancing its competitiveness in the pharmaceutical industry by leveraging professional investment resources [1] - The fund will primarily invest in sectors such as biomedicine, traditional Chinese medicine, medical devices, consumer healthcare, and medical services [1] Group 2 - The Zhaoying Huikang Fund is a component of the "Yuanshan Plan," initiated by Zhangzhou to promote the development of the traditional Chinese medicine industry and facilitate cross-strait integration in healthcare [2] - Pianzaihuang is identified as a key enterprise in the implementation of the "Yuanshan Plan," which includes the establishment of six funds totaling 6 billion yuan [2] - The successful registration of the Zhaoying Huikang Fund marks it as the third fund to complete the process under the Yuanshan medical health fund initiative, with additional funds in progress [2]

Core Viewpoint - The company is actively managing its raw material supply and exploring new procurement channels for natural ingredients, particularly focusing on the import of natural cow bile from Argentina, while maintaining its commitment to product quality through the exclusive use of natural cow bile in its main product, Pizhou Huang [1][2]. Group 1: Raw Material Management - The company has two musk bases located in Sichuan and Shaanxi, with strict adherence to legal and regulatory requirements for their operation and management [1]. - To ensure a stable supply of raw materials, the company is closely monitoring market dynamics and price trends, employing diversified procurement strategies, and maintaining stable relationships with suppliers [1]. - The company is actively engaging with the new policy allowing the import of natural cow bile from Argentina, although the current import scale is small and has minimal short-term impact on domestic market prices [1]. Group 2: Product Quality and Pricing Strategy - The company exclusively uses natural cow bile in the production of Pizhou Huang, which is crucial for maintaining product quality and efficacy [2]. - The price of natural cow bile has increased significantly, with the procurement cost in 2024-2025 being over three times that of 2021, leading to increased production costs [2]. - In response to rising costs, the company adjusted the price of Pizhou Huang in May 2023, while also enhancing promotional efforts to mitigate the impact of price increases on sales [2]. Group 3: Strategic Initiatives and Corporate Development - The company is implementing the "Famous Doctors Enter Zhang" strategy to enhance healthcare services and expand its network of traditional Chinese medicine clinics, with plans to establish over 30 new clinics by Q1 2025 [3]. - The cosmetic division of the company has been progressively separated, achieving initial compliance with the five independence principles required for a listed company, and has completed its restructuring to become a joint-stock company [3].